Genome editing and metabolic engineering of alkaloid biosynthesis in plants (GEMPlant)

Bidragets beskrivning

In the current study, our aim is, for the first time, to apply CRISPR/Cas9 genome editing technology together with recently developed synthetic expression system (SES) for the regulation of alkaloid biosynthesis in plant sources, with the aim of establishment of biotechnological production system for target compounds scopolamine and anatabine. Scopolamine is a high-value anti-cholinergic drug which is currently extracted from cultivated plants. Anatabine, on the other hand is a novel drug lead currently actively investigated for various targets, e.g. neurological disorders. In this research, the aim is to use plant cell culture systems in an efficient and sustainable manner to provide high-value natural compounds. The knowhow created within this research will provide completely new concepts within plant metabolic engineering in diverse applications.
Visa mer

Startår

2020

Slutår

2025

Beviljade finansiering

Suvi Häkkinen Orcid -palvelun logo
543 241 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiprojekt

Övriga uppgifter

Finansieringsbeslutets nummer

330128

Vetenskapsområden

Industriell bioteknologi

Forskningsområden

Teollinen biotekniikka

Identifierade teman

molecular biology, biochemistry